Call for Abstract

Annual Conference on Atherosclerosis and Clinical Cardiology, will be organized around the theme “Advancements in management of Atherosclerosis”

Atherosclerosis 2016 is comprised of 18 tracks and 65 sessions designed to offer comprehensive sessions that address current issues in Atherosclerosis 2016.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

Atherosclerosis sometimes called hardening of the arteries can slowly narrow and harden the arteries throughout the body. When atherosclerosis affects the arteries of the heart, it’s called coronary artery disease. Heart diseases, such as coronary heart disease, heart attack, high blood pressure are the leading cause of death for men and women. Most of these deaths are from heart attacks caused by sudden blood clots in the heart’s arteries.

  • Track 1-1Coronary Artery Disease
  • Track 1-2Carotid Artery Disease
  • Track 1-3Peripheral Artery Disease
  • Track 1-4Chronic Kidney Disease
  • Track 1-5Coronary Micro vascular Disease
  • Track 1-6Atherosclerosis Aneurysm
  • Track 1-7Non-Coronary Atherosclerosis

Clinical Cardiology is a specialty of internal medicine. Clinical Cardiology is the area where patients are access to specialized inpatient and outpatient heart care and long-term management of their conditions. The clinical cardiology focuses on the diagnosis, medical management (use of medicines), and prevention of cardiovascular disease. Cardiologists are specialized in diagnosing and treating diseases or conditions of the heart and blood vessels and the cardiovascular system.

  • Track 2-1Advances in open heart surgery
  • Track 2-2Advance in bypass surgery
  • Track 2-3Electorphysiology
  • Track 2-4Cardiac rehabilitation

Coronary artery disease (CAD), also called heart disease, results from a complex process known as atherosclerosis (commonly called "hardening of the arteries"). In atherosclerosis, fatty deposits (plaques) of cholesterol and other cellular waste products build up in the inner linings of the heart’s arteries. This causes blockage of arteries and prevents oxygen-rich blood from reaching the heart (ischemia). 

  • Track 3-1Coronary Artery Calcification
  • Track 3-2Coronary Artery Stenosis
  • Track 3-3Peripheral Artery Disease
  • Track 3-4Aorta Atherosclerosis

Many factors lead to the risk for atherosclerosis. Some risks can be prevented, while others cannot. Atherosclerosis is a slow, progressive disease that may begin as early as childhood. Although the exact cause is unknown, it may start with damage, injury or hardening of the inner layer of an artery. The common causes for hardening of the arteries are high cholesterol, fat, aging, smoking, high blood pressure etc.

  • Track 4-1Cholesterol
  • Track 4-2High Blood Pressure
  • Track 4-3Diabetes
  • Track 4-4Obesity
  • Track 4-5Smoking & Tobacco Usage
  • Track 4-6Homocysteine

Atherosclerosis does not usually produce symptoms until blood circulation becomes restricted or blocked, leading to cardiovascular disease (CVD). The type of cardiovascular disease and its associated symptoms depends on where the blockage occurs. Conditions caused by atherosclerosis include peripheral arterial disease, angina, aneurysm, heart attack and stroke.

  • Track 5-1Congestive Heart Failure
  • Track 5-2Myocardial Infraction
  • Track 5-3Arrhythmias
  • Track 5-4Pulmonary Embolism
  • Track 5-5Cardiomyopathy

Atherosclerosis interpretations are the most common cause of deaths. The one test that can directly show blocked arteries is called angiography. Angiography is an "invasive" test. As atherosclerosis does not cause symptoms until cardiovascular disease occurs, screening allows treatment to be given to reduce the risk of cardiovascular disease developing.

  • Track 6-1Angiography
  • Track 6-2Electrocardiogram
  • Track 6-3Coronary Calcium Scoring by CT Scan
  • Track 6-4Stress Testing
  • Track 6-5Echocardiography
  • Track 6-6hs-CRP

Atherosclerosis often develops at branch points or curving portions along extracranial and intracranial large arteries, locations where blood flow is slowed and more turbulent. The internal carotid artery is particularly at risk.  Exactly where disease tends to occur, though, and how quickly it progresses apparently reflect the individual's genetic background. With time, such an accumulation can form an elevated plaque that protrudes into the vessel's lumen and significantly reduces blood flow. 

Viruses contribute to the pathogenesis of atherosclerosis either via direct infection of vascular cells or via the indirect effects of cytokines or acute phase proteins induced by infection at non-vascular sites. There are now a large number of different infectious agents that are linked with an increased risk of cardiovascular disease.

  • Track 7-1Vulnerable Plaque
  • Track 7-2Atheroma
  • Track 7-3Claudication
  • Track 7-4Herpes Virus Induced Atherosclerosis
  • Track 7-5Cytomegalovirus Induced Atherosclerosis

Cardiovascular disease develops 7 to 10 years later in women than in men and is still the major cause of death in women. The under-recognition of heart disease and differences in clinical presentation in women lead to less aggressive treatment strategies and a lower representation of women in clinical trials. Furthermore, self-awareness in women and identification of their cardiovascular risk factors needs more attention, which should result in a better prevention of cardiovascular events. It is assumed that exposure to endogenous oestrogens during the fertile period of life delays the manifestation of atherosclerotic disease in women. Although studies have shown that hormonal dysfunction in premenopausal women is associated with an increased risk of atherosclerosis and CHD events, it is still unclear whether the polycystic ovary syndrome (PCOS) is an independent risk factor for atherosclerosis.

  • Track 8-1Endothelial Dysfunction
  • Track 8-2Hyperlipidemia
  • Track 8-3Plaque Characteristics
  • Track 8-4Postmenopausal status

The plasma lipoproteins are the primary means of transport of cholesterol among tissues. In particular, the apo B-containing lipoproteins (VLDL, IDL and LDL) are important for the delivery of cholesterol from the liver to peripheral tissues, while HDL appear to mediate the reverse process of movement of cholesterol from tissues back to the liver. Both of these transport processes are necessary for efficient whole body cholesterol homeostasis, because the liver is the major site of both the production and excretion of cholesterol. However, deviations from a proper balance of transport of cholesterol, either increases in LDL levels or decreases in HDL cholesterol flux, may result in accumulation of cholesterol in extra hepatic tissues. Increased risk of atherosclerosis and CHD may be associated with elevation in the number of LDL particles, increase or decrease in LDL particle size, or changes in the composition of plasma LDL.

  • Track 9-1Cholesterol Micro Embolization
  • Track 9-2Lipoprotein Receptors
  • Track 9-3Lipid Oxidation & Peroxidation
  • Track 9-4Lipoprotein Lipase Activity

Hypertension is a common condition in which the long-term force of the blood against your artery walls is high enough that it may eventually cause health problems, such as heart disease. Blood pressure is determined both by the amount of blood your heart pumps and the amount of resistance to blood flow in your arteries. The more blood your heart pumps and the narrower your arteries, the higher your blood pressure. In most people with established essential hypertension, increased resistance to blood flow accounts for the high pressure while cardiac output remains normal.

  • Track 10-1Renal Hypertension
  • Track 10-2Pulmonary Hypertension
  • Track 10-3Hypertension Management
  • Track 10-4Pharmacological Therapeutics for Hypertension
  • Track 10-5Advanced Curative Approaches

Treatments for atherosclerosis may include heart-healthy lifestyle changes, medicines, and medical procedures or surgery includes, Lowering the risk of blood clots forming, Preventing atherosclerosis-related diseases, Reducing risk factors in an effort to slow or stop the build-up of plaque, Relieving symptoms and Widening or bypassing plaque-clogged arteries.

  • Track 11-1ACE Inhibitors
  • Track 11-2Statins
  • Track 11-3Calcium Channel Blockers
  • Track 11-4Surgery
  • Track 11-5Nutritional Therapeutics

Clinical trials in cardiology research investigations are being conducted in which people of cardiac failures or disorders volunteer to test new treatments, interventions or tests as a means to prevent, detect, treat or manage various cardiovascular diseases or medical conditions. Some investigations look at how people respond to a new intervention and the side effects which might occur. This helps to determine if a new intervention works, if it is safe, and if it is better than the interventions that are already available. Clinical trials might also compare existing interventions, test new ways to use or combine existing interventions or observe how people respond to other factors that might affect their health such as dietary changes.

In the battle against atherosclerosis, the stakes remain high. Atherosclerosis involves inflammation and build-up of fatty plaques, or atheroma within vessel walls, which eventually lead to the hardening and narrowing of the arteries. When an atheroma ruptures, a blood clot can form to trigger a heart attack or stroke.

Because development of atherosclerosis in the body is a complex process, researchers are labouring on many fronts to find new ways to understand and treat this serious disease.

  • Track 13-1Apo-A1 Milano
  • Track 13-2Ramifications of Torcetrapib
  • Track 13-3Nanobacteria
  • Track 13-4miRNAs in Atherosclerosis

Pediatric Cardiology is responsible for the diagnosis of congenital heart defects, performing diagnostic procedures such as echocardiograms, cardiac catheterizations and electrophysiology studies. The increasing number of neonates with congenital heart defects referred to the neonatal intensive care unit reflects the increasing awareness that the defects may be present. Chest radiography and ECG rarely assist in the neonatal diagnosis. Congestive heart failure in the fetus, or hydrops, can be detected by performing fetal echocardiography. Many of the pediatric heart defects such as patent ductus arteriosus interruption, vascular ring division, pericardial window, diaphragm placation, thoracic duct ligation, ligation of collateral vessels have been repaired using pediatric interventional cardiology. Apart from these techniques nursing and care for pediatric cardiac patients also plays an important role for the cure of pediatric cardiac patients.

  • Track 14-1Neonatal cardiac surgery
  • Track 14-2Nursing for pediatric cardiac patients
  • Track 14-3Pediatric cardiovascular surgery
  • Track 14-4Myocardial dysfunction
  • Track 14-5Pulmonary stenosis
  • Track 14-6Cardiac therapeutic agents

Advances in Cardiology Education presents the current thinking of international experts regarding the underlying mechanisms of cardiovascular risk and the pathogenesis and pathophysiology of heart and its related disorders. This session gives new insights into the relationship between arterial stiffness, cardiovascular diagnosis, vascular study and atherosclerosis, but also establishes the possible interactions with age and other cardiovascular factors such as high blood pressure, diabetes and hyperlipidemia.

For sustaining India's rapid economic growth entrepreneurship is the counteractant. Entrepreneur is an individual who, rather than working as an employee, runs a small business and assumes all the risk and reward of a given business venture, idea, or good or service offered for sale. The present conference creates a global platform to interact Entrepreneurs and the Investors globally  in the field of cardiology and cardiovascular diseases control, which is going to lead a healthy life ultimately to healthy world.

 

Atherosclerosis remains a major cause of death in industrialized countries. In vivo visualization of the atherosclerotic plaque and its components (calcifications, fibro cellular tissue, lipid core, haemorrhage, and thrombus), particularly in humans, will further elucidate the disease process and the effect of various types of interventions, and subsequently will have important clinical implications. Recently, angiography and ultrasound were the most common methods of analysing atherosclerotic disease. Angiography provides information on the degree of stenosis but only limited information on the morphology of the atherosclerotic plaque. Ultrasound is able to visualize the plaque and to demonstrate the presence of calcifications.